³Ô¹ÏÍøÕ¾

Latest

Latest oncology News | Page 2

  • Latest oncology news stories and updates. What is happening today? All recent oncology news and developments. Live coverage and timeline of oncology. All you need to know about oncology.
Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer
Liberals To Deliver $174.8 Million NWRH And Mersey Master Plan
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
Deflexifol clinical data presented at ASCO Gastrointestinal Cancers Symposium
Ramsay Health Care acknowledges World Cancer Day 2024
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Radiotherapy upgrade improves patient care
Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer…
Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy
Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance
New treatment for deadly uterine cancer
Prescient announces the results of PTX-100 Phase 1b study in T-cell lymphoma patients
Inside Nepean Hospital’s new Pharmacy Department
Examining outcomes in children with Down syndrome and acute lymphoblastic leukemia
Positive efficacy result for Immutep’s ‘efti’ in combination with MSD’s pembrolizumab
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
Datopotamab deruxtecan plus Imfinzi demonstrated robust and durable tumour responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA…
Tagrisso plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and…
Imfinzi plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
Free author event at Taree Library
Compound d16 reduces tumor growth and overcomes therapeutic resistance in mutant p53-bearing cancers
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01…
Australian-developed drug receives US FDA approval
Radiation therapists walk off the job at Canberra Hospital
Scalp cooling machine to be back in action as soon as possible to assist Queenslanders undergoing cancer treatment
Enhertu demonstrated strong and durable tumour responses in previously treated HER2-mutant advanced lung cancer in DESTINY-Lung02 Phase II trial
Datopotamab deruxtecan plus Imfinzi showed promising clinical activity in the first-line advanced non-small cell lung cancer setting in TROPION-Lung04 Phase Ib trial
FivepHusion says first patient treated in paediatric brain cancer trial
Coffs Harbour Set to Get the Latest in Emerging Breast Cancer Treatments
W.P. Holman Clinic provides much-needed support to Tasmanians
Tim Baker: impacts of prostate cancer on partners
Radiotherapy upgrade offers improved patient care
Technique shows how abnormal RNA splicing leads to disease
Imugene licenses allogeneic CAR-T with a potential registration study in 2024
Trial to fill 30-year knowledge gap in cancer surgery
Living well with advanced cancer
H1 and Q2 2023 results
Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients
Enhertu demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial
Ludwig Chicago study develops an innovative approach to classify metastases in colorectal cancer patients
Bringing new science to market
All systems go for remote monitoring technology
Gunnedah in shock over hospital revision
ICU Redevelopment at Epworth Eastern
Takeda’s COCKPI-T programme calls for applications
Imfinzi plus Imjudo demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four…

© 2024 - ³Ô¹ÏÍøÕ¾